PORT HUENEME, CA--(Marketwire - November 30, 2010) - Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) www.StellarBiotechnologies.com announces completion of preclinical toxicity and immunogenicity testing of Stellar KLH/SUBUNIT and Stellar KLH/IMG by independent laboratory, WuXi AppTech of St. Paul, MN (a wholly owned subsidiary of WuXi PharmaTech) in two preclinical studies, setting the stage for use of Stellar KLH/IMG in human studies.